Pseudorabies virus (PRV) is the causative agent of Aujeszky's disease. This pathogen has major economic consequences in pig husbandry, 10,11 as it can infect livestock and wild animals, resulting in increased morbidity and mortality. 2, 3 In general, PRV mainly infects pigs at various production phases, causing high mortality in newborn piglets and abortion in pregnant sows, and results in significant economic losses for the pork industry. 3 The infected animals displayed multiple clinical signs, including high fever (usually 40-42°C), depression, anorexia, cough, shivering, diarrhea, and systemic neurological symptoms. Infected pigs were emaciated and weak in appearance, and ultimately died. 8, 12 Unexpectedly, growing and finishing pigs also died during this epidemic period, with a reported mortality rate of 10-30%.
tinuous epitopes of PRV gB identified were associated with complement-dependent virus neutralization and induced a strong antibody response during natural infection of swine. 15 Although no quantitative correlation has been reported between antibody level and clinical outcome, it seems likely that antibodies against immunodominant regions could mediate the clearance of virus and virus-infected cells and contribute to protective immunity against PRV.
In our study, the main antigen coding region of the gB (1,044 bp) gene was cloned from the vaccine strain PRV China/HB/98. The polymerase chain reaction products were inserted into a pET28a plasmid. a The recombinant plasmids were then transformed into Escherichia coli BL21 (DE3) a and protein expression induced with 0.4 mM isopropyl-β-dthiogalactopyranoside (IPTG). After 4 hr of induction at 37°C, the cells were sonicated and centrifuged for 20 min at 12,000 × g, the inclusion bodies were collected, then purified, denatured, and refolded as described previously. 13 The amount of target protein was >90% of the total purified protein by gel scanning analysis using a commercial system. c Figure 1 shows the results of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), Western blot, and the effect of purification of the gB fusion protein.
Approximately 200 μL of gB protein (1 mg/mL) solution was added to 10 mL of colloidal gold solution (pH 7.0) with constant stirring for 30 min, and then 1 mL 0.02 M sodium borate (pH 7.0) containing 10% bovine serum albumin (BSA) was added and then stirred for 10 min to stabilize the conjugate. The colloidal gold-labeled antigen was washed twice with wash buffer (0.02 M sodium borate, pH 7.0; 1% BSA; 0.1% sodium azide) by centrifugation at 20,000 × g and 4°C for 25 min. The precipitate was resuspended in 1 mL wash buffer. SPA b (1.0 mg/mL) and swine anti-PRV antibody IgG (1.0 mg/mL) were dispensed by biojets c attached to a commercial dispenser c on cellulose ester membrane (300 mm × 25 mm) d as the test and control lines, respectively. The test and control lines were situated 0.5 cm apart at the center of the membrane. The membrane has a nominal capillary flow time of 120 sec/4 cm and a nominal membrane thickness of 135 μm. These reagents were applied in the form of dots applied at 50 dots/mL/cm to the membrane, and then dried for 1 hr at 40°C. Sample and absorbent pads were made from nonwoven, 100% pure cellulose fiber d The sample pad was cut to 15 mm × 300 mm and saturated with a buffer (pH 8.0) containing 20 mM sodium borate, 2.0% (w/v) sucrose, 2.0% (w/v) BSA, and 0.1% (w/v) NaN 3 and dried for 10 min at 72°C. The absorbent pad was cut to 20 mm × 300 mm. Then the sample pad, conjugate pad, blotted membrane, and absorbent pad were assembled on the plastic backing support board sequentially with a 1-2 mm overlap. The master card was cut to 3.0-mm wide strips using a guillotine cutter. c The strips were then sealed in a plastic bag with desiccant gel and stored at 4°C until used.
To use the immunochromatographic test strip, a serum sample was 50-fold diluted with normal saline solution first, then 100 μL diluted sample was applied to the sample pad, whereby the solution migrates toward the absorbent pad. With a positive sample, the antibody binds to the antigen conjugate forming a gold antigen-antibody complex, which binds to SPA and gives a red-colored band at the test-line region. The absence of this band suggests a negative result. Samples with ambiguous results were retested; if the test provided another ambiguous result, the sample was considered as negative. To serve as a procedural control, a red band at the control-line region always appears regardless of the presence of anti-PRV antibodies.
The specificity of the strip was determined with 265 reference serum samples, including The sensitivity of the immunochromatographic strip was tested with 100 PRV gB antibody-positive pig serum samples (which were screened by a commercial PRV gB enzyme-linked immunosorbent assay [ELISA] e ). Ninetysix samples gave a positive result, which indicated that the sensitivity of this strip was 96% (96/100).
A total of 296 serum samples derived from vaccinated or infected swine and 50 sera derived from naive swine were tested with the immunochromatographic strip and commercial PRV gB ELISA, e simultaneously. The immunochromatographic test strip provided clear positive or negative results with the 296 field samples. The strip and the commercial ELISA provided similar results ( Table 2 ). The agreement of the immunochromatographic test strip with the commercial PRV gB ELISA was 93.6% (277/296). This indicated that the 2 test methods show good correspondence.
In China, the first report of a PRV outbreak occurred in the 1950s; inactivated vaccines and gE gene-deleted vaccines with virus strains Bartha-K61, HB-98, and Bucharest were imported from Hungary to China in the 1970s. From the 1990s until late 2011, >80% of pigs in China were vaccinated with the Bartha-K61 vaccine, and pseudorabies was well controlled. However, beginning in late 2011, pseudorabies has occurred on many large pig farms in animals that have been vaccinated. Newly emerging variants of PRV compromise the protection provided by current vaccines and cause death in all ages of vaccinated pigs. To circumvent such problems, both killed or modified-live PRV vaccines based on current PRV variants have been developed. An inactivated gE and gI-deleted vaccine based on PRV ZJ01 was developed, and the vaccine can provide protection to the newly emerging variant PRV challenge. A live gE-deleted PRV vaccine was also reported to provide complete protection to lethal challenge with PRV variant TJ strain. Glycoprotein B, as a main protective antigen, was necessary in the PRV vaccine.
Immunization efficiency evaluation mainly depends on serological tests. The serological tests used most commonly for PRV antibody determination are the virus neutralization test, 1 ELISA, 4 and latex agglutination test. 14 Although these assays provide accurate and sensitive detection of PRV antibodies, they require specialized equipment and technical expertise. As intact virus is involved in these tests, there is the risk of incomplete inactivation and escape of virus from laboratories. The immunochromatographic strip is a technique in which a cellulose membrane is used as the carrier and a colloidal gold-labeled antigen or antibody is used as the tracer. This technique has several advantages over traditional immunoassays, such as simplicity of the procedure, rapid operation, immediate results, low cost, and no requirements for skilled technicians or expensive equipment. Because of these characteristics, the immunochromatographic strip test is suitable for on-site detection of antibodies or antigens. 6 The gB protein overexpressed in E. coli, and, as is commonly the case, formed insoluble inclusion bodies. A large fraction of this protein could be solubilized in a denaturing buffer, thus allowing its purification by Ni-chelation chromatography. The problem of obtaining refolded protein was found to be best achieved by rapid dilution. Variations in the final yield are found depending on the combination of expression level and the efficiency of the refolding. The conditions of expression, purification, and refolding of gB protein were optimized, and the results were demonstrated by SDS-PAGE and Western blot.
The new immunochromatographic strip was optimized, and positive and negative sera were tested. The specificity and sensitivity of the strip was 98.1% and 96.0% respectively, with no cross-reaction with other pathogen antibody-positive sera such as CSF, PRRS, PC, JE, FMD, and PP. A total of 277 out of 296 samples showed the same results when compared with the commercial PRV gB ELISA kit; the rate of agreement was 93.6%. These results illustrated that the new immunochromatographic strip showed good performance and can be applied in-clinic to the evaluation of gB antibodies of PRV.
The strip test developed in the present study can be performed rapidly and easily, requiring no special equipment and skilled personnel. Thus, it has the potential for use infield to monitor antibodies induced by PRV vaccines. The detection of PRV antibody is the basis for establishing a proper immune program and evaluating the effect of vaccination on swine. However, the strip cannot discern vaccineinduced antibodies and antibodies derived from natural exposure. Although there is a linear relationship between the extent of color of the test line and the titers of PRV antibodies, quantitative assay cannot be visualized clearly by the naked eye. Further investigations need to be focused on finding a portable strip reader to provide the end-user with options for on or off screening and quantitative results.
